Retatrutide vs Mounjaro: Triple Agonist vs Dual Agonist

The core difference between retatrutide and Mounjaro comes down to how many hormone targets each hits: retatrutide activates three receptors, while Mounjaro (tirzepatide) activates two. That extra target appears to translate into more weight loss, with retatrutide reaching higher figures in trials, but Mounjaro has a decisive practical advantage: it’s approved and available now, while retatrutide is still investigational. Here’s how the two compare and what the difference actually means.

The Fundamental Difference

Mounjaro (the diabetes brand of tirzepatide; Zepbound is the obesity version) is a dual agonist, activating the GLP-1 and GIP receptors. Retatrutide adds a third target, glucagon, making it a triple agonist. That third hormone brings increased energy expenditure and reduced liver fat, on top of the appetite suppression and metabolic effects the other two provide. So retatrutide isn’t a different kind of drug so much as a more comprehensive version of the same multi-target strategy.

Head to Head

Here’s how they compare on the key points.

Weight Loss: Retatrutide Edges Ahead

On raw weight loss, retatrutide appears to have the edge. Its trials have shown about 24% in mid-stage testing and up to roughly 28% in later, longer studies. Mounjaro/tirzepatide, by comparison, produced up to about 21% weight loss in its pivotal SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022. So retatrutide’s third target does seem to buy additional weight loss. That said, comparing across separate trials is imperfect, since populations and study designs differ, so the gap should be viewed as approximate rather than exact.

Availability: Mounjaro Wins Decisively

Here’s where the comparison flips. Mounjaro (and its obesity counterpart Zepbound) is FDA approved and widely available, with years of real-world use behind it. Retatrutide, for all its impressive trial numbers, is still investigational and only available through clinical trials, with approval still ahead. Consider a hypothetical patient deciding today: retatrutide’s numbers might look more appealing on paper, but it’s not something they can actually get, while tirzepatide-based treatment is available and proven. A slightly higher trial figure means little if you can’t access the drug.

Side Effects

Both cause the familiar gastrointestinal side effects (nausea, diarrhea, constipation), mostly mild to moderate. Retatrutide adds a distinctive skin-tingling sensation (dysesthesia) at higher doses that tirzepatide doesn’t typically produce, and its glucagon component means its full long-term profile is still being characterized. Tirzepatide, having been used by many people over several years, has a more established safety track record.

What This Means for You Right Now

Retatrutide is a promising future option, not a current one. Mounjaro and Zepbound (tirzepatide) are available today, and TrimRx offers brand tirzepatide options along with compounded tirzepatide and compounded semaglutide and other brand GLP-1 medications. If you want strong, multi-target weight loss that you can actually start now, tirzepatide-based treatment is the practical choice while retatrutide completes development.

Frequently Asked Questions

Is retatrutide better than Mounjaro?

On trial weight loss, retatrutide has produced higher figures (up to about 28% versus up to about 21% for tirzepatide), thanks to its third hormone target. But Mounjaro is approved and available now, while retatrutide is still investigational, so “better” depends on whether you value peak trial numbers or actual availability.

Why does retatrutide produce more weight loss?

It activates three hormone receptors (adding glucagon, which increases calorie burning and reduces liver fat) versus tirzepatide’s two. Engaging that extra pathway appears to produce additional weight loss in trials.

Can I get retatrutide instead of Mounjaro?

No. Retatrutide is investigational and available only through clinical trials. Mounjaro (tirzepatide) is FDA approved and available, and TrimRx offers tirzepatide-based options among its treatments.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.